What is Dr Lal Pathlabs Ltd (LALPATHLAB) share price today?

Dr Lal Pathlabs Ltd (LALPATHLAB) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/LALPATHLAB for the latest live price, technical analysis, and AI-powered insights.

How to analyse LALPATHLAB stock?

VestAI provides comprehensive LALPATHLAB stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Dr Lal Pathlabs Ltd in?

Dr Lal Pathlabs Ltd (LALPATHLAB) is in the Healthcare sector, Healthcare Service Provider industry on the NSE.

Dr Lal Pathlabs Ltd

Name: Dr Lal Pathlabs Ltd (LALPATHLAB) Financial Metrics
Creator: VestAI

LALPATHLAB

NSE· Healthcare

₹1,687.40

-45.30 (-2.61%)

Updated 11:27 am IST

52W Low · ₹1,272.6052W High · ₹1,784.00

Near 52W High

Market Cap

₹25662.81L Cr

Volume

2.13L

Prev Close

₹1,732.70

ISIN

INE600L01024

Orion Score

Fundamentals-based quality & risk · not a recommendation

71/100

Quality

Dr Lal Pathlabs Ltd scores 71/100 (Quality) on the Orion Score — strong business quality (85), moderate growth (64), strong balance-sheet safety (85) and rich valuation (19). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 1.2× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 6/9Altman Z Safe(9.10)Beneish M Clean(-2.26)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

67/100

Strong

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.08x — lean balance sheet

QUALITY

High Quality

ROCE 24.2% — excellent capital efficiency

MOMENTUM

Neutral

RSI 55.7 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q3 FY2026

P/E Ratio: 48.54
ROCE: 24.22%
ROE (1Y): 21.48%
D/E Ratio: 0.08x
OPM: 20.79%
TTM EPS: ₹31.66
Dividend Yield: 91.00%
Qtrly Sales: ₹659.80 Cr
Qtrly Profit: ₹90.50 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q3 2026	₹659.8	₹90.5	20.8%	₹5.41
Q1 2026	₹669.8	₹132.4	23.5%	₹7.92
Q4 2025	₹602.42	₹154.84	23.1%	—
Q3 2025	₹596.7	₹96.7	19.9%	₹5.79
Q2 2025	₹660.2	₹129.2	25.3%	₹7.74

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2025	₹2,461.22	₹487.14	₹789.03	22.8%
FY 2024	₹2,226.5	₹357.74	₹678.41	21.0%
FY 2023	₹2,016.64	₹238.85	₹531.55	17.4%
FY 2022	₹2,087.4	₹344.8	₹613.2	35.3%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
LALPATHLAB ★	₹25,663 Cr	48.54	24.22%	21.48%	0.08x	20.79%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹88,228 Cr	25.64	12.55%	9.93%	0.21x	15.11%
ASTERDMAster DM Quality	₹71,372 Cr	108.60	8.93%	10.07%	0.46x	13.98%
ABBOTINDIAAbbott India Limited	₹59,615 Cr	38.42	36.14%	34.46%	0.04x	27.01%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹2,716.79	₹2,455.96	₹2,385.56	₹2,353.22
Equity	₹2,172.72	₹1,849.28	₹1,666.3	₹1,508.08
Total Debt	₹157.43	₹246.93	₹419.5	₹532.43
Cash	₹292.63	₹360.93	₹263.73	₹378.19
Net Debt	—	—	—	—
Working Capital	₹961.16	₹663.12	₹503.33	₹375.16

Shareholding Pattern

Q1 FY2027

Promoter

54.91%

FII

17.35%

DII

14.2%

Public

13.54%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	54.91% ↑	17.35% ↓	14.2% ↓	13.54% ↑
Q3 FY2026	53.21%	20.29% ↓	19.2% ↑	6.94% ↑
Q2 FY2026	53.21% ↓	21.86% ↑	18.22% ↑	6.07% ↓
Q1 FY2026	53.79% ↓	21.69% ↓	17.62% ↑	6.22% ↑
Q4 FY2025	53.91%	23.9% ↓	15.79% ↑	5.84% ↑
Q3 FY2025	53.91% ↓	26.82%	12.88% ↑	5.82% ↓
Q2 FY2025	53.92% ↓	26.82% ↑	12.6% ↑	6.02% ↓
Q1 FY2025	54.6%	25.43%	12.42%	6.95%

Corporate Actions

Ex-Date	Action	Details
2026-06-25	DIVIDEND	Dividend - Rs 4 Per Share
2026-02-05	DIVIDEND	Interim Dividend - Rs 3.50 Per Share

Funds Holding This Stock

131 mutual fund schemes

NJ Flexi Cap Fund Direct GrowthNJ

3.97%

₹102 Cr

Tata India Innovation Fund Direct GrowthTATA

3.80%

₹53 Cr

NJ ELSS Tax Saver Scheme Direct GrowthNJ

3.33%

₹11 Cr

PGIM India Healthcare Fund Direct GrowthDHFL_PRAMERICA

3.27%

₹3 Cr

Bandhan Healthcare Fund Direct GrowthIDFC

3.00%

₹9 Cr

Quantum Ethical Fund Direct GrowthQUANTUM

2.84%

₹3 Cr

DSP Nifty Smallcap250 Quality 50 Index Fund Direct GrowthDSP

2.76%

₹9 Cr

NJ Balanced Advantage Fund Direct GrowthNJ

2.71%

₹92 Cr

Tata Multicap Fund Direct GrowthTATA

2.60%

₹86 Cr

Mirae Asset Healthcare Fund Direct GrowthMIRAE_ASSET

2.54%

₹79 Cr

Analyse LALPATHLAB with Orion AI

Ask: "Is Dr Lal Pathlabs Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Dr Lal Pathlabs Ltd (LALPATHLAB) Stock

Dr Lal Pathlabs Ltd is listed on the NSE under the Healthcare sector, Healthcare Service Provider industry. ISIN: INE600L01024. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.